Influence of the levels of thyroid hormones on the result of radiofrequency ablation for atrial fibrillation: literature review
Abstract
Introduction. Atrial fibrillation is one of the most common, clinically significant cardiac arrhythmias and is associated with an increased risk of mortality, hospitalization, and deterioration in the quality of life. The prevalence of atrial fibrillation averages 1% and tends to increase with age. It is well known that aberrations of thyroid hormones have a proarrhythmogenic effect and increase the risk of cardiovascular disease. Currently, radiofrequency ablation is actively used to treat atrial fibrillation, which in most cases has high efficiency and lasting effect. However, recurrence of atrial fibrillation may occur in some patients even after radiofrequency ablation. It is known that thyroid function is closely related to the success of radiofrequency ablation and risk of relapse of atrial fibrillation after the procedure. The aim of this literature review is to determine what is already known about the effect of thyroid and thyroid-stimulating hormones levels on the outcome of radiofrequency ablation of atrial fibrillation and to analyze previous studies. Materials and methods. A complete review of the literature on atrial fibrillation and the relationship between thyroid and thyroid hormones and recurrence of atrial fibrillation after radiofrequency ablation was conducted to examine the effect of hormone levels on the success of radiofrequency ablation and recurrence of atrial fibrillation after the procedure. Results. Data from a significant number of studies suggest that the incidence of atrial fibrillation recurrence remains high after radiofrequency ablation and that thyroid hormones affect the success of radiofrequency ablation even within normal ranges. Evidence may also suggest that patients with thyroid dysfunction, even in the presence of subclinical forms, may require better monitoring of thyroid function prior to the procedure, which may reduce the incidence of atrial fibrillation recurrence. Conclusions. It should be noted that the assessment and correction of all modifying risk factors before radiofrequency ablation can prevent recurrence of supraventricular paroxysmal arrhythmias, improve the prognosis and overall quality of life in patients in this group.
Downloads
References
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (eacts). European Heart Journal. 2020;42(5):373–498.
Rao MP, Pokorney SD, Granger CB. Atrial fibrillation: A review of recent studies with a focus on those from the Duke Clinical Research Institute. Scientifica. 2014;2014:1–11.
Michelena HI, Ezekowitz MD. Atrial fibrillation: are there gender differences?. J Gend Specif Med. 2000;3(6):44-49.
Liżewska-Springer A, Dąbrowska-Kugacka A, Lewicka E, Drelich Ł, Królak T, Raczak G. Echocardiographic predictors of atrial fibrillation recurrence after catheter ablation: A literature review. Cardiology Journal. 2020;27(6):848–56.
Lee E, Choi E-K, Han K-D, Lee HJ, Choe W-S, Lee S-R, et al. Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study. PLOS ONE. 2018;13(12).
Кravchenko VI, Тоvkay ОА, Rakov ОV, Тronko МD. Epidemiolohiya avtoimunnoho tyreoyidytu. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine). 2021;17(2):136–44.
Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology. 2018;14(5):301–16.
Biban BG, Lichiardopol C. Iodine Deficiency, Still a Global Problem?. Curr Health Sci J. 2017;43(2):103-111. DOI: https://doi.org/10.12865/CHSJ.43.02.01
Knyazkova II, Bilovol AN. Disfunktsiya shchitovidnoy zhelezy i serdechnaya nedostatochnost'. Zdorov'ya Ukraini. 2016; https://health-ua.com/article/4874-disfunktciya-shitovidnoj-zhelezy-i-serdechnaya-nedostatochnost.
Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Research. 2009;2(1).
Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed – a review for Primary Care. Clinical Medicine & Research. 2016;14(2):83–92.
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology. 2016;14(1):39–55.
Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart Journal. 2017;69(4):545–50.
Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist DeBakey Cardiovascular Journal. 2017;13(2):55.
Xu J, Luc JG, Phan K. Atrial fibrillation: Review of Current Treatment Strategies. Journal of Thoracic Disease. 2016;8(9).
Baman JR, Passman RS. The future of long-term monitoring after catheter and surgical ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2022;33(8):1911-1918. DOI: https://doi.org/10.1111/jce.15375
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (eacts). European Heart Journal. 2020;42(5):373–498.
Meshkova MS, Doronin OV. Obgruntuvannya dotsilʹnosti zastosuvannya radiochastotnoyi kateternoyi destruktsiyi z metoyu likuvannya fibrylyatsiyi peredserdʹ. Ukrayinsʹkyy zhurnal sertsevo-sudynnoyi khirurhiyi. 2020;1 (38):57-61. DOI: https://doi.org/10.30702/ujcvs/20.3803/015057-061
Management strategies for atrial fibrillation. Atrial Fibrillation in Clinical Practice. 2000;:129–35.
Shu Z, Chen M, Wang Q, Lai J, Zhao J, Zhuo C, et al. High-normal thyroid function and recurrence of atrial fibrillation after catheter ablation: A prospective observational study [Internet]. Cardiology. Karger Publishers; 2021 [cited 2022Dec14]. Available from: https://www.karger.com/Article/FullText/517092
Garvanski I. Predictors of recurrence of AF in patients after radiofrequency ablation [Internet]. ECR Journal. 2019 [cited 2022Dec14]. Available from: https://www.ecrjournal.com/articles/predictors-recurrence-af-patients-after-radiofrequency-ablation
Huang RD, Lin JJ, Gong KZ, Chen LL, Fan L, Zhang FL, et al. Comparison of amiodarone and propafenone in blanking period after radiofrequency catheter ablation in patients with atrial fibrillation: A propensity score-matched study. BioMed Research International. 2020;2020:1–8.
Brynza M, Lisova N. Two-year outcomes of pulmonary vein isolation and cava-tricuspid isthmus radiofrequency ablation vs pharmacological only antiarrhythmic therapy: A single center experience. EUREKA: Health Sciences. 2022;(1):10–6.
Zink MD, Chua W, Zeemering S, Biase L, Antoni LB, David C. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation [Internet]. Academic.oup.com. OUP Academic. Oxford University Press; 2020 [cited 2022Dec14]. Available from: https://academic.oup.com/europace/article/22/9/1337/5877521
Kim YG, Boo KY, Choi J-I, Choi YY, Choi HY, Roh S-Y, et al. Early recurrence is reliable predictor of late recurrence after radiofrequency catheter ablation of atrial fibrillation. JACC: Clinical Electrophysiology. 2021;7(3):343–51.
Boersma L, Koźluk E, Maglia G, de Sousa J, Grebe O, Eckardt L, et al. Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter gold duty-cycled phased radiofrequency ablation catheter: Quality of life and 12-month efficacy results from the Gold Atrial Fibrillation Registry. EP Europace. 2020;22(6):888–96.
Chew DS, Black-Maier E, Loring Z, Noseworthy PA, Packer DL, Exner DV, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation. Circulation: Arrhythmia and Electrophysiology. 2020;13(4).
Sawasaki K. Predictors of atrial fibrillation recurrence after ablation. Atrial Fibrillation - Diagnosis and Management in the 21st Century. 2022.
Sultan A, Lüker J, Andresen D, Kuck KH, Hoffmann E, Brachmann J, et al. Predictors of atrial fibrillation recurrence after catheter ablation: Data from the German Ablation Registry. Scientific Reports. 2017;7(1).
Dretzke J, Chuchu N, Agarwal R, Herd C, Chua W, Fabritz L, et al. Predicting recurrent atrial fibrillation after catheter ablation: A systematic review of Prognostic Models. EP Europace. 2020;22(5):748–60.
Zhang Y, Dedkov EI, Teplitsky D, Weltman NY, Pol CJ, Rajagopalan V, et al. Both hypothyroidism and hyperthyroidism increase atrial fibrillation inducibility in rats. Circulation: Arrhythmia and Electrophysiology. 2013;6(5):952–9.
Bruere H, Fauchier L, Bernard Brunet A, Pierre B, Simeon E, Babuty D, et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. The American Journal of Medicine. 2015;128(1):30–7.
Wongcharoen W, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Chung F-P, et al. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. Heart Rhythm. 2015;12(9):1956–62.
Tang RB;Liu DL;Dong JZ;Liu XP;Long DY;Yu RH;Hu FL;Wu JH;Liu XH;Ma CS; High-normal thyroid function and risk of recurrence of atrial fibrillation after catheter ablation [Internet]. Circulation journal : official journal of the Japanese Circulation Society. U.S. National Library of Medicine. Available from: https://pubmed.ncbi.nlm.nih.gov/20508382/
Sousa PA, Providência R, Albenque JP, et al. Impact of Free Thyroxine on the Outcomes of Left Atrial Ablation Procedures. Am J Cardiol. 2015;116(12):1863-1868. DOI: https://doi.org/10.1016/j.amjcard.2015.09.028
Wei S-bin, Wang W, Liu N, Chen J, Guo X-yuan, Tang R-bo, et al. U-shaped association between serum free triiodothyronine and recurrence of atrial fibrillation after catheter ablation. Journal of Interventional Cardiac Electrophysiology. 2018;51(3):263–70.
Morishima I, Okumura K, Morita Y, et al. High-Normal Thyroid-Stimulating Hormone Shows a Potential Causal Association With Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation [published correction appears in J Am Heart Assoc. 2018 Oct 2;7(19):e02707]. J Am Heart Assoc. 2018;7(14):e009158. Published 2018 Jul 12. DOI: https://doi.org/10.1161/JAHA.118.009158
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
